Biogen Inc. (BIIB)

About Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

As of November 3, 2026, Biogen Inc. (BIIB) stock rose to $252.23, up 1.29% (+$3.22) versus the previous close. On the day, shares have traded between $246.25 and $252.28. That puts BIIB near the top of its 52-week range of $148.51 to $258.78. Biogen Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $37.49 billion, with about 266.4K shares changing hands.

Latest BIIB news

• Should You Buy The Dip In Alnylam Stock?trefis.com· Nov 2, 9:39 AM ET
• What Just Happened To Alnylam Stock?trefis.com· Oct 30, 12:51 PM ET
• Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC SaysYahoo Finance· Oct 29, 11:58 AM ET
• Alphabet downgraded, eBay upgraded: Wall Street's top analyst callsYahoo Finance· Oct 29, 9:47 AM ET
• Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026Yahoo Finance· Oct 29, 6:59 AM ET
• What to expect from Regeneron’s (REGN) Q3 earningsYahoo Finance· Oct 29, 6:11 AM ETREGN
• Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash FlowYahoo Finance· Oct 29, 1:18 AM ET
• Biogen Q3 Earnings Call Highlightsmarketbeat.com· Oct 28, 6:04 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want BIIB headlines, alerts and AI research in one place? Create a free account →

• $AMGN So now, sitting at a mere 10M Market Cap, Seastar (ICU) will generate more revenue than that in 2027 with today's removal of the registry requirement. 7 BDDs, with the most recent for Sepsis as a standalone indication. TAM easily in the billions once adult use approv…

  @SparkyReturns· Nov 3, 10:58 AM ET· Bullish

• Everything you need to know about the $18.9M Biogen ($BIIB) Settlement Payout Q: What happened? A: Biogen allegedly misled investors about the commercial launch of Aduhelm, its Alzheimer’s treatment, by overstating payer support and suggesting that Medicare coverage was automa…

  @11thestate· Nov 2, 8:29 AM ET

• $PMN $PMN When $LLY and $BIIB works with IgG1 and ProMIS hat the same isotype target but 0 ARIA why would someone compare $ABOS versus Promis ? Soon after unblinding it will show ProMIS is the best AD in class!

  @GoforProMIS· Nov 2, 7:21 AM ET· Bullish

• $BIIB Excellent article that nails exactly where BIIB stands right now. So if you want to update your BIIB knowledge or get acquainted with BIIB, this is a must read. https://everyticker.com/quote/BIIB/analysis/biogen-s-immunology-inflection-why-the-apellis-acquisition-marks-t…

  @NVDAMillionaire· Nov 2, 2:23 AM ET

• $BIIB is still paying for Apellis in its cost of sales, and the filing puts a number on it. The inventory fair value step-up from the deal ran 100.0 million dollars through cost of sales in the third quarter alone, and 169.7 million dollars over nine months. Total step-up was …

  @KryptonResearch14· Nov 1, 1:31 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →